Biotechnology
625 companies in this industry
Insider Buys (30d)
47
$45.41M
Insider Sells (30d)
291
$755.06M
Top Companies by Market Cap
VRTXVertex Pharmaceuticals Incorporated
$111.71BREGNRegeneron Pharmaceuticals, Inc.
$77.87BARGXargenx SE
$45.82BALNYAlnylam Pharmaceuticals, Inc.
$41.24BINSMInsmed Incorporated
$30.79BRVMDRevolution Medicines, Inc.
$29.51BUTHRUnited Therapeutics Corporation
$25.13BBNTXBioNTech SE
$24.56BMRNAModerna, Inc.
$21.42BRPRXRoyalty Pharma plc
$21.20BRecent Insider Trades
| Date | Ticker | Company | Insider | Role | Type | Shares | Avg Price | Value |
|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | IRD | Opus Genetics, Inc. | YERXA BENJAMIN R | director, officer: President | Sell | 7,470 | $5.24 | $39.1K |
| Apr 27, 2026 | IRD | Opus Genetics, Inc. | Gagnon Robert E. | officer: Chief Financial Officer | Sell | 7,842 | $5.18 | $40.7K |
| Apr 27, 2026 | IRD | Opus Genetics, Inc. | Magrath George | director, officer: Chief Executive Officer | Sell | 9,511 | $5.22 | $49.6K |
| Apr 27, 2026 | IRD | Opus Genetics, Inc. | SCHACHLE JOSEPH K | officer: Chief Operating Officer | Sell | 4,697 | $5.22 | $24.5K |
| Apr 27, 2026 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | director | Sell | 384,549 | $18.47 | $7.10M |
| Apr 27, 2026 | IRD | Opus Genetics, Inc. | Zaremba Rabourn Amy | officer: Head of Fin. Quality Assurance | Sell | 1,641 | $5.20 | $8.5K |
| Apr 27, 2026 | UTHR | United Therapeutics Corporation | ROTHBLATT MARTINE A | director, officer: Chairperson & CEO | Sell | 9,500 | $564.81 | $5.37M |
| Apr 27, 2026 | IMDX | Insight Molecular Diagnostics Inc. | BROADWOOD PARTNERS, L.P. | 10 percent owner | Buy | 570,184 | $3.56 | $2.03M |
| Apr 27, 2026 | IRD | Opus Genetics, Inc. | Jayagopal Ashwath | officer: Chief Scientific & Dev. Ofc. | Sell | 7,542 | $5.19 | $39.2K |
| Apr 24, 2026 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | director | Sell | 40,000 | $3.61 | $144.4K |
| Apr 24, 2026 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | Sell | 165,150 | $15.77 | $2.60M |
| Apr 24, 2026 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | director | Sell | 6,000 | $89.96 | $539.8K |
| Apr 24, 2026 | ARWR | Arrowhead Pharmaceuticals, Inc. | Apel Daniel Joseph | officer: Chief Financial Officer | Sell | 13,095 | $71.35 | $934.3K |
| Apr 24, 2026 | IMVT | Immunovant, Inc. | Stout Jay S | officer: Chief Technology Officer | Sell | 2,754 | $29.62 | $81.6K |
| Apr 24, 2026 | IMVT | Immunovant, Inc. | Girao Tiago | officer: Chief Financial Officer | Sell | 25,760 | $29.62 | $763.0K |
| Apr 24, 2026 | ADPT | Adaptive Biotechnologies Corporation | RUBINSTEIN JULIE | officer: President and COO | Sell | 57,180 | $13.96 | $798.4K |
| Apr 24, 2026 | ARWR | Arrowhead Pharmaceuticals, Inc. | Hamilton James C | officer: Chief Medical Officer | Sell | 10,000 | $75.00 | $750.0K |
| Apr 24, 2026 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | officer: Chief Operating Officer | Sell | 300 | $90.00 | $27.0K |
| Apr 24, 2026 | UTHR | United Therapeutics Corporation | EDGEMOND JAMES | officer: CFO AND TREASURER | Sell | 10,000 | $572.34 | $5.72M |
| Apr 24, 2026 | PHVS | Pharvaris N.V. | Lesage Anne | officer: Chief Early Development | Sell | 7,600 | $30.05 | $228.4K |
| Apr 24, 2026 | PHVS | Pharvaris N.V. | Lu Peng | officer: Chief Medical Officer | Sell | 7,101 | $30.05 | $213.4K |
| Apr 24, 2026 | UTHR | United Therapeutics Corporation | PATUSKY CHRISTOPHER | director | Sell | 2,910 | $569.00 | $1.66M |
| Apr 24, 2026 | UTHR | United Therapeutics Corporation | ROTHBLATT MARTINE A | director, officer: Chairperson & CEO | Sell | 9,500 | $572.35 | $5.44M |
| Apr 24, 2026 | PHVS | Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 7,100 | $30.05 | $213.4K |
| Apr 23, 2026 | ALLO | Allogene Therapeutics, Inc. | Yoshiyama Annie | officer: SVP, Finance | Sell | 9,586 | $2.31 | $22.1K |
| Apr 23, 2026 | SGMO | Sangamo Therapeutics, Inc. | Davis Gregory D | officer: Head of Research & Technology | Sell | 69,827 | $0.25 | $17.7K |
| Apr 23, 2026 | PTCT | PTC Therapeutics, Inc. | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 2,850 | $70.91 | $202.1K |
| Apr 23, 2026 | SGMO | Sangamo Therapeutics, Inc. | Dubois-Stringfellow Nathalie | officer: SVP-CHIEF DEVELOPMENT OFFICER | Sell | 345,942 | $0.26 | $89.2K |
| Apr 23, 2026 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | officer: Chief Research Officer | Sell | 9,100 | $39.09 | $355.7K |
| Apr 23, 2026 | AXSM | Axsome Therapeutics, Inc. | Maizel Ari | officer: Chief Commercial Officer | Sell | 7,500 | $182.42 | $1.37M |
| Apr 23, 2026 | PRLD | Prelude Therapeutics Incorporated | Bonita David P | director, 10 percent owner: | Buy | 2,815,315 | $4.44 | $12.50M |
| Apr 23, 2026 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | director | Sell | 10,952 | $20.01 | $219.2K |
| Apr 23, 2026 | PRLD | Prelude Therapeutics Incorporated | ORBIMED ADVISORS LLC | director, 10 percent owner: | Buy | 2,815,315 | $4.44 | $12.50M |
| Apr 23, 2026 | UTHR | United Therapeutics Corporation | ROTHBLATT MARTINE A | director, officer: Chairperson & CEO | Sell | 9,500 | $576.56 | $5.48M |
| Apr 22, 2026 | CLNN | Clene Inc. | Ugwumba Chidozie | 10 percent owner | Sell | 65,663 | $6.14 | $403.1K |
| Apr 22, 2026 | BCDA | BioCardia, Inc. | Altman Peter | director, officer: President and CEO | Buy | 1,000 | $1.23 | $1.2K |
| Apr 22, 2026 | BCAX | Bicara Therapeutics Inc. Common Stock | Hyep Ivan | officer: Chief Financial Officer | Sell | 9,200 | $23.00 | $211.6K |
| Apr 22, 2026 | KPTI | Karyopharm Therapeutics Inc. | Rangwala Reshma | officer: EVP & Chief Medical Officer | Sell | 449 | $8.94 | $4.0K |
| Apr 22, 2026 | PRLD | Prelude Therapeutics Incorporated | BAKER BROS. ADVISORS LP | director, 10 percent owner: | Buy | 2,252,252 | $0.00 | $225.23 |
| Apr 22, 2026 | QSI | Quantum-Si incorporated | Hawkins Jeffrey Alan | director, officer: President & CEO | Sell | 167,424 | $1.00 | $167.5K |
| Apr 22, 2026 | QSI | Quantum-Si incorporated | Keyes Jeffry R. | officer: Chief Financial Officer | Sell | 74,763 | $1.00 | $74.8K |
| Apr 22, 2026 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | director | Sell | 834,302 | $19.75 | $16.48M |
| Apr 22, 2026 | UTHR | United Therapeutics Corporation | ROTHBLATT MARTINE A | director, officer: Chairperson & CEO | Sell | 9,500 | $570.42 | $5.42M |
| Apr 21, 2026 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Sell | 5,000 | $47.67 | $238.4K |
| Apr 21, 2026 | CYTK | Cytokinetics, Incorporated | Malik Fady Ibraham | officer: EVP Research & Development | Sell | 3,500 | $65.69 | $229.9K |
| Apr 21, 2026 | NUVB | Nuvation Bio Inc. | Wentworth Kerry | officer: CHIEF REGULATORY OFFICER | Sell | 36,750 | $5.01 | $184.3K |
| Apr 21, 2026 | INCY | Incyte Corporation | CAGNONI PABLO J | officer: President, Global Head of R&D | Sell | 18,667 | $96.50 | $1.80M |
| Apr 21, 2026 | PTGX | Protagonist Therapeutics, Inc. | Ali Asif | officer: Chief Financial Officer | Sell | 1,750 | $105.47 | $184.6K |
| Apr 21, 2026 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | director | Sell | 55,345 | $44.67 | $2.47M |
| Apr 21, 2026 | RAPP | Rapport Therapeutics, Inc. Common Stock | Third Rock Ventures V, L.P. | 10 percent owner | Sell | 426,005 | $40.32 | $17.18M |
Showing 1–50 of 338
1 / 7
...